Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Exparel to Bupivacaine With Dexamethasone in TAP Block

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female patients undergoing scheduled abdominal surgery at Emory University Hospital or Emory University Hospital Midtown~* Patients willing and able to provide written informed consent~Exclusion Criteria:~* Patients less than 18 years of age, since Exparel has not been studied in this age group~* Patients who are pregnant or lactating, since Exparel has not been shown to be safe in this population, and because of potential drug transfer to child~* Patients with uncontrolled diabetes since dexamethasone may cause hyperglycemia~* Patients with liver dysfunction, since bupivacaine is hepatically metabolized~* Patients with renal failure, since bupivacaine is renally excreted, defined as requiring hemodialysis or renal replacement therapy~* Patients with allergy to one of the study drugs~* Patients with local infection, which may be exacerbated by dexamethasone~* Patients with significant opioid tolerance, defined as taking at least 60 mg oral morphine per day, 3 mg oral oxycodone per day, 25 mcg/hr fentanyl patch, 25 mg oral oxymorphone per day, 8 mg of oral hydromorphone per day or an equianalgesic dose of another opioid for one week or longer~* Patients with known coagulopathy, since bleeding risk is higher Patients who are getting neuraxial anesthesia for surgery

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group 1-Exparel (Type: ACTIVE_COMPARATOR): Bupivacaine Extended-Release Liposome Injection (Exparel)will be administered via TAP block procedure
- Group 2-Bupivacaine and Dexamethasone IV (Type: ACTIVE_COMPARATOR): Bupivacaine and Dexamethasone Injection will be administered via TAP block procedure.

Based on this trial design, predict the completion outcome and termination type (if applicable).